$Nikola (NKLA.US)$ I recommend if you own NKLA $Cardio Diag...
$Nikola(NKLA.US$ I recommend if you own NKLA $Cardio Diagnostics(CDIO.US$ buy some $Esperion Therapeutics(ESPR.US$ They trade around the same stock price, yet ESPR could jump to $4 a share in a few weeks on Judge ruling in favor for $300 million milestone for ESPR after 11/23 . Read my message article from 11/11 , This is part of it > My friend is a CVS pharmacist says now Insurance is covering ESPR drugs NEXLIZET and NEXLETOL to lower bad Cholesterol LDL-C for Statin intolerant patients and those that have maxed out taking a Statin drug and don't want to take a PCSK9 injection, such as $Amgen(AMGN.US$ Repatha drug.
$CVS Health(CVS.US$ is stocking the drugs now and sales are steadily increasing. ESPR sells 2 statin alternative medications NEXLIZET and NEXLETOL, Statin drugs are the #1 selling drugs in the world, 70 to 90 million Americans take Statin drugs and 18 million Americans are maxed out taking a Statin and need to take a PCSK9 injection or take an oral pill with just 3 options ESPR's 2 drugs or Ezetimibe.
ESPR partner Daiichi Sankyo Europe DSE is selling under a different label name and now out selling PCSK9 drugs with script growth of 127%. and now has 158,000 scripts up 35,000 in 3 months, which is shown by ESPR earnings reported on Nov 7th last week, also DSE owes $300 million for a milestone payment and another $900 million on label change to ESPR, ESPR stock has tanked from $6 to under $2 in March this year when DSE said they weren't paying the $300 milestone saying the drug was not effective above 15% DSE owed $200 million if 15% to 19% effective of $300 million above 20% this is for NEXLETOL which is Bempedoic Acid and reported by New Engalnd Journal is 23% effective. I personally paid a pattern and contract attorney and he actually bought ESPR stock after OCT 25th because he is 100% confident after reviewing the case ESPR will get paid. A NY Judge is going to rule based on the contract agreement after November 22nd 2023. ESPR Stock could run up to $4 a share this year on the ruling, its $1.15 now and the company is valued at $120 million, they have $140 million in yearly sales and next year presciption growth will surge because of label change for primary prevention is expected by March 31st 2024. Esperion has total of $1.8 billion in milestone agreements. Label change will get ESPR to over 1 million yearly prescriptions and will generate $4 billion in yearly sales, the stock will reach $40 a share. Do your own research and you will see this biotech has incredible growth prospects. Search Youtube for the CBS news special https://www.youtube.com/watch?v=IaU7NF1xMfg
$CVS Health(CVS.US$ is stocking the drugs now and sales are steadily increasing. ESPR sells 2 statin alternative medications NEXLIZET and NEXLETOL, Statin drugs are the #1 selling drugs in the world, 70 to 90 million Americans take Statin drugs and 18 million Americans are maxed out taking a Statin and need to take a PCSK9 injection or take an oral pill with just 3 options ESPR's 2 drugs or Ezetimibe.
ESPR partner Daiichi Sankyo Europe DSE is selling under a different label name and now out selling PCSK9 drugs with script growth of 127%. and now has 158,000 scripts up 35,000 in 3 months, which is shown by ESPR earnings reported on Nov 7th last week, also DSE owes $300 million for a milestone payment and another $900 million on label change to ESPR, ESPR stock has tanked from $6 to under $2 in March this year when DSE said they weren't paying the $300 milestone saying the drug was not effective above 15% DSE owed $200 million if 15% to 19% effective of $300 million above 20% this is for NEXLETOL which is Bempedoic Acid and reported by New Engalnd Journal is 23% effective. I personally paid a pattern and contract attorney and he actually bought ESPR stock after OCT 25th because he is 100% confident after reviewing the case ESPR will get paid. A NY Judge is going to rule based on the contract agreement after November 22nd 2023. ESPR Stock could run up to $4 a share this year on the ruling, its $1.15 now and the company is valued at $120 million, they have $140 million in yearly sales and next year presciption growth will surge because of label change for primary prevention is expected by March 31st 2024. Esperion has total of $1.8 billion in milestone agreements. Label change will get ESPR to over 1 million yearly prescriptions and will generate $4 billion in yearly sales, the stock will reach $40 a share. Do your own research and you will see this biotech has incredible growth prospects. Search Youtube for the CBS news special https://www.youtube.com/watch?v=IaU7NF1xMfg
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
